arrow
S

Stephen J. Russell

vyriad inc
H指数:106
被引数:4.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Extended Survival in a Dog with Primary Bone Hemangiosarcoma Following Treatment with Neoadjuvant Oncolytic Virotherapy and Standard of Care

使用新辅助溶瘤病毒疗法和标准治疗方案治疗的一例犬原发性骨血管肉瘤患者的生存期延长

2025-09-231
OAAI
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
MBIO
IF4.7
2024-02-142
OAAI
Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma
2023-12-013
OAAI
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy

在新型药物诱导治疗时代,新诊断的多发性骨髓瘤患者进行前期自体干细胞移植后的反应加深

2022-11-013
OAAI
DNA barcoded competitive clone-initiating cell analysis reveals novel features of metastatic growth in a cancer xenograft model

DNA条形码竞争性克隆起始细胞分析揭示了癌症异种移植模型中转移性生长的新特征

2022-07-221
OAAI
Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome

维生素d缺乏症在肾淀粉样变性患者中普遍存在,并与肾脏预后相关

2022-06-210
OAAI
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

复发难治性T细胞淋巴瘤患者单剂量全身溶瘤VSV病毒治疗的临床活性

2022-02-1727
OAAI
Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

在美国引入新疗法后多发性骨髓瘤的死亡率趋势

LEUKEMIA
IF13.4
2021-10-2650
PREAI
IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers

免疫COV v2.0: 用于测量SARS-CoV-2-Neutralizing抗体滴度的高通量临床测定的开发和验证

MSPHERE
IF3.1
2021-06-3015
OAAI